Vaxcyte, Inc. — Director's Dealing 2022

Dec 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-12-23

Reporting Person: Wassil Jim (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-23	Common Stock	M	105371	$2.42	Acquired	147715	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-23	Stock Option (right to buy)	$2.42	M	105371	Disposed	2029-12-16	Common Stock (105371)	Direct

Footnotes

F1: The shares of Common Stock received upon this option exercise remain subject to the restrictions on transfer set forth in a Lock-Up Agreement dated October 24, 2022.

F2: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.